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1. Introduction 
Estrogen signaling is essential in the initiation and development of neoplasia in mammary 
gland. In the past several decades, extensive efforts have been dedicated to understand the 
underlying mechanisms of this important signaling pathway in mammary carcinogenesis, 
which have facilitated the development of anti-estrogen therapy, the first targeted therapy 
for human cancer.  
It has been well documented that the diverse activities of estrogens and anti-estrogens are 
mediated by specific receptors designated as estrogen receptors (ERs). Currently, there are 
two identified ERs, ER- and ER-, both of which are ligand-activated transcription factors 
that stimulate target gene transcription. Compelling evidence indicates that estrogens, 
especially 17-estradiol (E2), up-regulate the expression and function of c-Myc and cyclin 
D1, activate cyclin E-Cdk2 complexes and promotes cell cycle progression from G1 to S 
phase in mammary epithelial cells. Thus, stimulation of target gene expression by ERs in 
response to estrogens is prevailingly thought to be responsible for estrogen-stimulated 
mammary carcinoma initiation and progression.  
Despite the clarity with which ERs have been shown to act as ligand-dependent 
transcription factors, it became apparent now that not all of the activities mediated by ERs 
are accomplished through a direct effect on gene transcription. Another signaling pathway 
(also known as a non-classic, non-genomic, extra-nuclear or membrane-initiated signaling 
pathway) exists that involves cytoplasmic signaling proteins, growth factor receptors and 
other membrane-initiated signaling pathways. Several intracellular signaling pathways have 
been shown cross-talking with the membrane-initiated estrogen signaling: the adenylate 
cyclase pathway, the phospholipase C pathway, the G-protein-coupled receptor-activated 
pathways, the PI3K/AKT and the MAPK pathways.  
Currently, the identity of the membrane-based estrogen receptor that mediates non-genomic 
estrogen effects has not been fully established. ER-, two forms of ER-, full-length (66-kDa) 
and short form (46-kDa) have been found on or near the plasma membrane and mediates 
membrane-initiated estrogen signaling. In addition, there is also evidence indicating that 
GPR30, an orphan G-protein-coupled-receptor, mediates the rapid, non-genomic responses 
to estrogens. In 2005, our laboratory identified and cloned a novel variant of ER-, which 
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has a molecular weight of 36-kDa and thus we have termed it ER-36. This ER- variant 
differs from the original 66 kDa ER- (ER-66) by lacking both transcriptional activation 
domains (AF-1 and AF-2) but retaining the DNA-binding domain and partial dimerization 
and ligand-binding domains. ER-36 is predominantly expressed on the plasma membrane 
of both ER-positive and –negative breast cancer cells, mediates membrane-initiated estrogen 
and anti-estrogen signaling such as activation of the MAPK/ERK and PI3K/AKT signaling 
pathways and stimulation of cell proliferation. Thus, ER-36 is a novel membrane-
associated estrogen receptor that mediates membrane-initiated estrogen and anti-estrogen 
signaling in both ER-positive and -negative breast cancer cells.  
In this chapter, we highlight the historical understanding of non-genomic estrogen signaling 
and its role in cell survival and proliferation, and specifically illustrate the biological 
function and the possible underlying mechanisms of ER-36 in non-genomic estrogen and 
anti-estrogen signaling in both ER-positive and –negative breast cancer cells. We also 
discuss the integral roles of EGFR, Src and STAT5 in the non-genomic estrogen signaling 
mediated by ER-36 and the complex regulatory network among ER-66, 46 and 36. In 
addition, the novel biology of non-genomic estrogen signaling mediated by ER-36 also has 
significance for understanding the physiology of bone remodeling. Thus, ER-36-mediated 
signaling has a broad appeal in physiology of non-classical estrogen targeting tissues and 
general cancer research.  
2. Estrogen receptors and genomic estrogen signaling 
Estrogen signaling is pivotal in the establishment and maintenance of reproductive function 
in men and women. It is also involved in normal development and physiology of bone, 
liver, cardiovascular and neuronal systems. Inappropriate estrogen signaling is involved in 
osteoporosis, atherosclerosis and Alzheimer’s disease and is essential in the initiation and 
development of neoplasia in breast and endometrial cancers (Nilsson et al., 2001). Hence, it 
is important to understand the molecular mechanisms by which this important signaling 
pathway functions, so its participation in a wide variety of different biological processes can 
be clarified, including how its dysregulation contributes to different diseases and even 
neoplastic transformation. 
The diverse physiological and pathological functions of estrogens are mediated by specific 
receptors designated as estrogen receptors (ERs). In 1986, the cloning of the estrogen 
receptor (ER) was first reported (Green et al., 1986; Greene et al., 1986). Until 1996, it was 
assumed that there was only one ER responsible for all of the physiological and 
pharmacological effects of natural and synthetic estrogens and anti-estrogens. However, in 
1996, a second ER was cloned (Kuiper et al., 1996). Currently, the first ER discovered is 
referred to as ER-, while the second is called ER-. 
ER- and ER- share a common structural architecture (Reviewed by Kong et al., 2003; 
Zheng et al., 2003). Both are composed of three independent but interacting functional 
domains: the N-terminal A/B domain, the C or DNA-binding domain, and the D/E/F or 
ligand-binding domain. The N-terminal domain of ERs encodes a ligand-independent 
activation function (AF-1), a region involved in interaction with co-activators, and 
transcriptional activation of target genes. The DNA-binding domain or C domain contains a 
two zinc-finger structure, which is involved in receptor dimerization and binding to specific 
DNA sequences. The C-terminal E/F domain is a ligand-binding domain that mediates 
ligand binding, receptor dimerization, nuclear translocation, and a ligand-dependent 
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transactivation function (AF-2). The relative contributions that both AF-1 and AF-2 exert on 
transcriptional control vary in a cell-specific and DNA promoter-specific manner (Berry et 
al., 1990; Tzukerman et al., 1994). 
It is well established that estrogen receptors are members of the nuclear receptor 
superfamily of ligand-activated transcription factors that control various physiological 
processes. It is prevailingly thought that this control often occurs through the regulation of 
gene transcription (Reviewed by Katzenellenbogen & Katzenellenbogen, 2000; McDonnell & 
Norris, 2002).  The estrogen receptor utilizes multiple mechanisms to either activate or 
repress transcription of its target genes. These mechanisms include: (a) direct interaction of 
the ligand-occupied receptor with DNA at a consensus estrogen response elements (ERE, 
GGTCAnnnTGACC) followed by recruitment of transcriptional coregulator or mediator 
complexes (Reviewed by Klinge, 2001), (b) interaction of the ligand-occupied ER with other 
transcription factors such as AP-1 (Kushner at al., 2000), Sp1 (Safe, 2001) or NF-B (McKay & 
Cidlowski, 1999), or (c) indirect modulation of gene transcription via sequestration of 
general/common transcriptional components (Harnish et al., 2000; Speir et al., 2000). In 
addition, the ability of an estrogen receptor to regulate transcription through these 
mechanisms appears to be cell-type specific, perhaps due to differences in the complement 
of transcriptional co-regulatory factors available in each cell type (Cerillo et al., 1998; Evans 
et al., 2001; Maret et al., 1999).  Also, transcriptional regulation is dependent upon the nature 
of the ligand, with various natural and synthetic selective estrogen receptor modulators 
(SERM) acting as either estrogen receptor agonists or antagonists through these various 
mechanisms (Shang & Brown, 2002; Katzenellenbogen & Katzenellenbogen, 2002; Margeat 
et al., 2003). 
3. Estrogen signaling and breast cancer 
Experimental and clinical evidence for the role of endogenous estrogens in normal 
development of mammary glands and breast cancer etiology has been well documented 
(Reviewed by Feigelson & Henderson, 1996). Estrogen signaling is involved in mammary 
epithelial cell proliferation and differentiation. Dysregulated estrogen signaling increases 
the rate of cell proliferation and thus the risk for development of breast cancer. 
ER- is expressed in approximately 15-30% of luminal epithelial cells and not at all in any 
other cell types in the normal human breast (Clarke et. al., 1997). However, dual label 
immunofluorescent technique revealed that ER- expressing cells are separate from those 
labeled with proliferation markers such as Ki67 and cyclin A in both normal human and 
rodent mammary glands (Clarke et al., 1997; Zeps et al., 1999). This is in direct contrast to 
estrogen action in breast cancer cells, where estrogens, especially 17-estradiol (E2), 
functions as potent mitogens through promoting cell cycle progression from G1 to S phase 
(Prall et al., 1998; Altucci et al., 1996 & 1997). Thus, it is thought that estrogens directly 
interact with ERs in ER-positive human breast cancer cells, where they induce 
transcriptional activation of “immediate early” and cyclin genes, and promote cell cycle 
progression. Consistent with its role in mammary carcinogenesis, ER- expression is 
increased at the earliest stages of ductal hyperplasia and increases even more with 
increasing atypia, such that most cells in atypical ductal hyperplasias and in ductal cancer in 
situ of low and intermediate grade contain ER- (Khan et. al., 1994). As ER- expression 
increases during breast cancer development, the inverse relationship between ER- 
expression and cell proliferation become dysregulated (Shoker et. al., 1999 a and b). 
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Approximately 70% of invasive breast carcinomas express the ER- and most of these 
tumors contain ER- positive proliferating cells (Clarke et. al., 1997).  
Currently, ER-is the most widely used marker in diagnosis of human breast cancer. Breast 
cancers are diagnosed either as ER-positive or -negative depending on the existence or 
absence of ER-. At the onset, 46%-77% of breast cancers are ER-positive (Robertson et. al., 
1996). The ER-positive tumors are histologically well differentiated and diploid, and 
patients with ER-positive tumors generally have a better prognosis since they respond well 
to anti-estrogen treatment (Clark et. al., 1984; Osborne et. al., 1980). ER-negative breast 
cancers that account for about one third of breast cancers diagnosed, however, are more 
malignant and aggressive through a still unknown mechanism (Sheikh et. al., 1994), and 
they generally respond poorly to anti-estrogen treatment.  
ER-negative breast cancers are often considered to be the result of tumor progression from 
ER-positive premalignant lesions or ER-positive breast cancers by epigenetic alterations 
such as promoter methylation (Ferguson et. al., 1995) or ER- protein degradation by the 
proteasome system after hypoxia in non-vascularized tumors (Stoner et. al., 2002). However, 
immunohistochemical studies in human breast cancers showed that some proliferative 
ductal lesions and many high-grade ductal carcinomas in situ (DCIS) are ER--negative 
(Roger et. al., 2000), suggesting some ER-negative breast cancers may be progressed directly 
from ER-negative premalignant lesions.  
4. Non-genomic estrogen signaling 
It become clear now that estrogens elicit two signaling pathways; the first requires hours to 
days to result in transcriptional changes of target genes and is known as genomic, classic or 
nuclear signaling pathway while the second occurs in seconds to minutes after estrogen 
treatment and usually initiates at the plasma membrane. Thus, the second signaling 
pathway is also known as a non-classic, non-genomic, extra-nuclear or membrane-initiated 
signaling pathway which is mediated by estrogen binding proteins associated with the 
plasma membrane and employs various cytoplasmic signaling proteins, growth factor 
receptors and G-protein-coupled-receptor signaling pathways (Segars & Driggers, 2002; 
Driggers & Segars, 2002; Kelly & Levin, 2001; Levin, 2002; Hammes & Levin, 2007).  
Pietras and Szego first described the rapid estrogen signaling more than 30 years ago 
(Pietras & Szego, 1975 &1977), noting immediate calcium fluxes in endometrial cells induced 
by estrogen and specific binding sites at the outer surfaces of isolated endometrial cells. 
Quick estrogen responses were also recorded in neuroendocrine tissue such as a rapid rise 
of intracellular calcium in pituitary cells, which leads to cell depolarization within 1 min 
(Dufy et al., 1979). Rapid estrogen signaling also induces prolactin secretion from pituitary 
tumor cells (Watson et al., 1999). Such signaling of estrogens has also been described in 
uterine (Aronica et al., 1994) and ovarian cells (Morley et al., 1992; Tesarik & Mendoza, 1997) 
as well as bone (Endoh et al., 1997; Longo et al., 2004; Sylvia et al., 2001), vascular 
endothelial (Russell et al., 2000; Lu et al., 2004) and neuronal cells (Kelly et al., 1977; 
Mermelstein et al., 1996), indicating that the rapid, non-genomic estrogen signaling is 
involved in various physiological and pathological estrogen activities.  
Non-genomic estrogen signaling has been also documented in breast cancer cells for cell 
proliferation and survival (Song et al., 2002; Migliaccio et al., 1996; Ahmad et al., 1999; 
Lobenhofer et al., 2000; Castoria et al., 1999 & 2001). These findings strongly suggest that the 
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rapid, non-genomic estrogen signaling is involved in estrogen-induced proliferation in 
breast cancer cells.  
5. Nature of membrane-based estrogen receptor 
While it is clear that membrane-initiated estrogen signaling exists, the identity of the 
membrane-based estrogen receptor that mediates these rapid estrogen effects, especially the 
effects in mammary epithelial cell proliferation and survival, has not been fully established. 
Laboratory evidence indicated that both ER- and ER- are involved in the rapid, non-
genomic estrogen signaling (Razandi et al., 1999). However, evidence also suggests that 
more than one membrane-initiated signaling pathway is associated with estrogen action. 
Data from several laboratories using the membrane-impermeable compound 17-estradiol-
bovine serum albumin (E2-BSA) indicates the existence of two functionally distinct 
membrane-associated pathways: one sensitive to anti-estrogens and one resistant (Chen et 
al., 1999; Russell et al., 2000; Watters et al., 1997). For example, ER-/knockout mice 
retained rapid estrogen-stimulated membrane effects in neurons, which were not blocked by 
anti-estrogen ICI-182, 780 (Gu, et. al., 1999). These findings suggest that another membrane-
based ER may exist since all known ERs are sensitive to anti-estrogen inhibition. As a 
consequence, an orphan G-protein coupled receptor, GPCR30, and some other unknown 
proteins have been reported to mediate this anti-estrogen resistant non-genomic estrogen 
signaling.  
6. ER-α 
A large body of experimental evidence indicated that ER- is involved in both genomic and 
non-genomic estrogen signaling. Immunofluorescent staining of non-permeabilized pituitary 
tumor cells with anti-ER- antibodies revealed a punctuated staining pattern on cell surface 
although most ER- were localized in cell nuclei (Watson et al., 1999). ER- associated with the 
plasma membrane is also detected by a panel of antibodies targeting different domains of ER-
 in intact breast cancer cells and in breast cancer specimens (Pietras et al., 2005; Kim et al., 
2006). The findings that transfection of the nuclear ER- cDNA into ER-“null” Chinese 
hamster ovary (CHO) cells leads to expression of both membrane and nuclear ER- further 
support the notion that membrane-associated ER- is derived from the same transcript as 
nuclear ER-(Razandi et al., 1999). However, recent evidence indicates that the CHO-K1, 
Rat2-fibroblasts and COS7 cells previously considered as ER “null’ cells and extensively used 
to transfect ER cDNAs in order to demonstrate rapid estrogen signaling actually exhibit strong 
non-genomic estrogen signaling such as activation of the MAPK/ERK before transfection 
(Nethrapalli et al., 2005), suggesting these cells already posses some unknown proteins other 
than classical ERs that mediate the rapid estrogen signaling. 
It is widely accepted that estrogen signaling promotes cell proliferation in target cells. 
However, the explanation of this effect of estrogen signaling simply by the function of ER- 
is confounding. When ER- was expressed in ER-“null” CHO cells (Kushner et. al., 1990), 
and human cervical cancer HeLa cells (Touitou et. al., 1990), E2 failed to stimulate cell 
growth. On the contrary, E2 inhibited cell proliferation and even induced cell apoptosis. 
Likewise, the ER-negative immortal MCF10A breast epithelial cells (Pilat et. al., 1996), and 
MDA-MB-231 breast cancer cells (Jiang & Jordan, 1992) were both growth inhibited by 
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estrogen when stably transfected with ER- cDNA. These experimental results argue 
against a positive function of the well-known ER- alone in mitogenic estrogen signaling. 
7. ER-β 
ER- acts as a classical ligand-induced transcription factor. Like ER-, ligand-bound ER- 
functions by regulating downstream target genes. ER- also heterodimerizes with ER- and 
modulates ER- function (Reviewed by Harris, 2007; Deroo & Buensuceso, 2010). ER- has 
been shown to be S-palmitoylated, which facilitates the localization of ER- at the plasma 
membrane to mediate the rapid, non-genomic estrogen effects (Marino & Ascenzi, 2008). 
Indeed, the involvement of ER- in rapid, non-genomic estrogen signaling has been 
documented when ER- cDNA was introduced into CHO cells (Razandi et al., 1999) In 
colon cancer, pro-apoptotic activities of ER- have been reported to be mediated by 
membrane-initiated signaling; induction of ER- via the MAPK/p38 signaling pathway, 
which in turn leads to downstream apoptotic events (Caiazza et al., 2007), indicating a 
potential role of ER- as a tumor suppressor. In addition, inhibition of ER- palmitoylation 
in colon cancer cells abrogated the pro-apoptotic activity of ER-(Galluzzo et al., 2007), 
suggesting that non-genomic effects mediated by membrane–associated ER-is important 
for its pro-apoptotic function.  
The biological significance of ER- in breast cancer has not been well established. 
Approximately 70% of breast tumor express ER- and most tumor co-express both ER- and 
–(Dotzlaw et al., 1997; Fuqua et al., 1999 & 2003). Studies indicated that ER- expression in 
human breast cancer is associated with a poorer prognosis, compared with tumors that only 
express ER- (Speirs et al., 1999). ER- expression is associated with elevated levels of 
proliferation markers, Ki67 and cyclin A, in human breast cancer (Jensen et al., 2001) These 
studies suggested that ER- may promote cell proliferation and breast cancer progression.  
In contrast, accumulating evidence indicated that ER- acts as a tumor suppressor in breast 
cancer. ER- is expressed in both normal and malignant mammary glands (Warner et al., 
2000; Speirs et al., 2002). In the rodent mammary gland, ER- expressing cells can proliferate 
but the majority cells that express proliferation markers do not express either ER (Saji et al., 
2001). The levels of ER- expression are highest in normal mammary gland and are 
decreased as tumors progress from pre-invasive to invasive (Leygue et al., 1998; Iwao et al., 
2000; Roger et al., 2001). The presence of ER- in breast cancer confers a more favorable 
prognosis and is associated with node-negative, low-grade tumors (Jarvinen et al., 2000) as 
well as a greater disease-free survival rate (Omoto et al., 2001). Several laboratory studies 
demonstrated that ER- inhibited angiogenesis and malignant growth of T47D breast tumor 
xenograft and malignant growth of MCF7 breast cancer cells in vitro and in nude mice 
(Hartman et al., 2006; Paruthiyil et al., 2004). Intriguingly, ER- also inhibited proliferation 
of ER-negative breast cancer MDA-MB-231 cells in a ligand-independent manner whereas 
ER- inhibition of MDA-MB-231 cell proliferation is estrogen-dependent (Lazennec et al., 
2001). These results indicate that ER- negatively regulates mitogenic estrogen signaling.  
8. ER-α46 
Previously, it was reported that a 46-kDa antigen is tightly associated with ER- in human 
breast cancer samples (Diaz-Chico et. al., 1988). This 46-kDa antigen is enriched in the cell 
www.intechopen.com
 
ER-Alpha36 Mediates Non-Genomic Estrogen and Anti-Estrogen Signaling in Breast Cancer Cells 291 
cytosol and could be recognized by an isolated monoclonal antibody, E476, raised against 
the human ER- (Diaz-Chico et. al., 1988). Similarly, Jozan (1991) later reported that there 
are two species of ER with different molecular weight (65 and 47 kDa), and three species of 
tumors (36% containing the highest form of ER alone, 49% bearing the two forms in variable 
amounts, and 15% bearing only the minor form). These results strongly suggest that two 
different forms of ER- exist at different ratios in human breast cancer.  
In 2000, Flouriot et. al. cloned a 46-kDa isoform of ER- and demonstrated that the 46-kDa 
isoform lacks the first 173 amino acids (A/B or AF-1 domain) and is derived from 
alternative splicing of the ER- gene by skipping exon 1. This alternative splicing event 
generates an mRNA that has an AUG in a favorable Kozak sequence for translation 
initiation in frame with the remainder of the open reading frame of ER- (Flouriot et. al., 
2000). This new isoform of ER- is named as ER-46 and the original one as ER-66. ER-46 
forms homo-dimers and binds to an ERE, and it can also form heterodimers with ER-66 
(Flouriot et. al., 2000). Furthermore, the ER-46/66 heterodimers form preferentially over 
the ER-66 homodimers and ER-46 acts competitively to inhibit transactivation mediated 
by AF-1 domain of ER-66 but without effect on AF-2-dependent transactivation (Floutiot 
et. al., 2000). Therefore, ER-46 is a naturally occurring isoform of ER- that regulates 
genomic estrogen signaling mediated by the AF-1 domain of ER-66. 
Previously, two forms of ER-, full-length (66-kDa) and short form (46-kDa) were co-
purified with 5’ nucleotidase, a plasma membrane-marker enzyme (Marquez & Pietras, 
2001), suggesting a possible role of ER-46 in the rapid, non-genomic estrogen signaling. 
Recently, ER-46 was localized on the plasma membrane, in the cytosol, and nucleus of 
endothelial cells and mediated rapid estrogen signaling such as activation of the 
Src/PI3K/AKT signaling and stimulation of NO synthesis (Kim & Bender, 2005; Li et. al., 
2003; Reviewed by Moriarty et al., 2006), further confirming that the ER-46 isoform 
functions as a membrane-associated estrogen receptor.  
Although it is clear now that ER-46 is involved in both genomic and non-genomic estrogen 
signaling, its function in breast cancer has been less investigated. Forced expression of ER-
46 inhibited proliferation of MCF-7 breast cancer cells and cyclin D1 promoter activity 
(Penot et al., 2005). Overexpression of both ER-46 and ER-66 in ER-negative MDA-MB-
231 cells revealed that ER-46 inhibited basal transcription of the estrogen responsive gene 
pS2 while estrogen treatment released this inhibition (Metivier et al., 2004). Recently, 
expression levels of ER-46 was found to be down-regulated in tamoxifen-resistant breast 
cancer cells and re-introduction of ER-46 into these cells inhibited cell proliferation and ER-
66-regulated gene transcription (Klinge et al., 2010). Thus, these results suggest that ER-
46 may function as a negative-regulator of mitogenic estrogen signaling in ER-positive 
breast cancer cells. 
9. ER-α36 
In 2005, our laboratory identified a 5.4 kb cDNA clone from a normal human edometrium 
cDNA library (RZPD clone number: DKFZp686N23123) and later cloned this cDNA from a 
human placenta cDNA library (Wang et al., 2005). This cDNA clone harbors a 310 amino 
acid open-reading frame that can produce a protein with a predicted molecular weight of 
35.7 kDa. To differentiate it from ER-66 and 46, and apply consistent nomenclature, this 
novel isoform of ER- was named as ER-36.  
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The cDNA sequence of the open-reading frame matches 100% to the DNA sequence of the 
exons 2 to 6 of the ER-66 gene. The 5’untraslated region (5’UTR) of the cDNA showed 
100% homology to the DNA sequence of the first intron of the ER-66 gene. Thus, the 
transcript of this ER- isoform is initiated from a previously unidentified promoter in the 
first intron of the ER-66 gene (Figure 1, Zou et al., 2009). A small, non-coding novel exon in 
the first intron of the ER-66 gene was designated as exon 1’. The exon 1’ is then spliced 
directly into the exon 2 of the ER-66 gene and continues from exon 2 to exon 6 of the ER-
66 gene. Exon 6 is then spliced to an exon located 64,141 bp downstream of the ER-66 
gene (Figure 1). The cDNA sequence encoding the last 27 amino acids and the 4,293 bp 
3’untranslated region (3’UTR) was matched 100% to a continuous sequence from the 
genomic sequence of clone RP1-1304 on chromosome 6q24.2-25.3 (GeneBank accession 
number AL78582), indicating the remaining cDNA sequence of this novel ER- isoform is 
transcribed from one big exon of 4,374 bp located downstream of the ER-66 gene. This 
exon is thus designated as exon 9 to reflect the extra exon beyond the previous reported 
eight exons for ER-66 gene (Figure 1). All of these splicing events are supported by the 
identification of perfect splice donors and acceptors at the splice juncture. The protein ER-
36 can be produced from a perfect Kozak sequence located in the second exon, the same 
initiation codon used to produce ER-46 (Flouriot et. al., 2000). ER-36 differs from the ER-
66 by lacking both transcriptional activation domains (AF-1 and AF-2) but retaining the 
DNA-binding and dimerization domains, and partial ligand-binding domains. It also 
possesses an extra, unique 27 amino acid domain to replace the last 138 amino acids 
encoded by exon 7 and 8 of the ER-66 (Figure 2). Thus, ER-36 is another naturally 
occurring novel isoform of ER- that may play an important role in both genomic and non-
genomic estrogen signaling. Currently, there are three major ER- isoforms observed in ER-
positive breast cancer MCF7 cells that correspond to three mRNA variants generated from 
different promoter usage and alternative splicing (Figure 2). 
 
 
Fig. 1. Genomic organization of the human ER-36 gene. The locations of multiple 
promoters of human ER-66 gene are shown as arrows. The translation start and stop 
codons are indicated as AUG and UGA. The common exons are shown as numbered open 
boxes. The extra exon that is beyond the 8 exons of the human ER-66 gene is numbered as 
9 in the open box. The intron 1 is also shown with the exon 1’ in the open box. The lower 
panel shows mRNA structure of human ER-36 isoform. 
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Fig. 2. Domain structure and expression of human estrogen receptor- variants in ER-
positive breast cancer MCF7 cells. (A). Domain structure representation of human ER- 
isoforms. Domains (labeled A–F), and activation function domains (AF-1 and -2) are shown. 
The function of each domain is indicated. The last 27 amino acids of human ER-36 are 
indicated as a filled box. (B). Western blot analysis of three human ER- isoforms in MCF7 
cells with an anti-ER-66 antibody (H222). 
10. GPR30 
Previously, different laboratories demonstrated the existence of two distinct membrane-
associated pathways: one sensitive to anti-estrogens and one resistant (Chen et al., 1999; 
Russell et al., 2000; Watters et al., 1997). These results suggest that another membrane-
associated estrogen receptor may exist since both ER- and - are sensitive to anti-estrogen 
inhibition.   
An orphan G protein-coupled receptor, GPR30 was reported to mediate the rapid, non-
genomic estrogen signaling that was insensitive to ICI 182,780; estrogen stimulates changes 
of Ca2+ currents and cAMP signaling in cells expressing GPR30 (Revankar et al., 2005) and 
activates the MAPK/ERK phosphorylation and the PI3K/Akt signalling pathways via 
transactivation of the EGFR pathway in ER-negative but GPR30-positive breast cancer cells 
(Filardo et al., 2000 & 2007). Thus, GPR30 was considered as a novel type of membrane-
associated estrogen receptor that mediates the rapid, non-genomic estrogen signaling.  
There are also reports that challenge the role of GPR30 as a novel estrogen receptor. A study 
showed that introduction of GPR30 anti-sense oligonucleotides failed to block the 
MAPK/ERK activation and cell growth induced by estrogen in ER-positive breast cancer 
cells (Ahola et al., 2002). Pedram et al. (2006) failed to observe the cAMP or ERK activation in 
GPR30-positive, ER-negative breast cancer cells. Another study demonstrated that the 
GPR30 selective agonist G1 failed to exert estrogenic effect in two classical estrogen target 
organs, the uterus and the mammary gland (Otto et al., 2008). Recently, Otto et al. generated 
GPR30-deficient mice and demonstrated that the development of reproductive organs was 
unimpaired in these mice and the estrogenic responses in the uterus and the mammary 
gland were completely maintained in GPR30-deficient animals (Otto et al., 2009).  
Recently, our group reported that knockdown of GPR30 expression in ER-negative breast 
cancer SK-BR-3 cells down-regulated the expression levels of ER-┙36 (Kang et al., 2010b). 
Introduction of a GPR30 expression vector into GPR30 non-expressing cells induced 
endogenous ER-36 expression and GPR30 activated the promoter activity of ER-36 via an 
AP-1 binding site located in the 5’-flanking region of ER-36 (Kang et al., 2010b). Thus, ER-
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36 is a downstream target gene of GPR30-mediated signaling and the previously reported 
activities of GPR30 as a membrane-based estrogen receptor are through its ability to induce 
ER-┙36 expression.  
11. Other putative estrogen receptors 
Other unknown proteins that may be involved in the rapid, non-genomic estrogen signaling 
have been also reported.  For an example, a report that E2 activated the MAPK/ERK 
signaling in un-trasnfected CHO-K1, COS7 and Rat2-fibroblasts (Nethrapalli et al., 2005) 
suggested the existence of an unidentified membrane-associated mER. Recently, we 
reported that un-transfected COS7 cells express high levels of endogenous ER-36 (Kang et 
al., 2010b) and found that CHO-K1 cells also express ER-36 (Kang et al., unpublished 
observations), suggesting that ER-36 may mediates the rapid, non-genomic estrogen 
signaling observed in these cells.  
Another unique membrane-associated ER with an estimated molecular weight of 63-65 kDa, 
referred to as ER-X, is developmentally regulated differently from both ER- and –. Its 
pharmacological profile was also different from ER- and –, even with some features 
opposite to those shown for these two receptors (Toran-Allerand et al., 2002). For examples, 
ER-X mediated rapid estrogen signaling was not sensitive to anti-estrogen, and the 
association of Hsp90 is required for the inactive state of ER- while ER-X requires to be 
associated with hsp90 for its activity (Toran-Allerand et al., 2002). Whereas ER-X shares 
limited similarities with ER-36, such as reaction with antibodies to the ligand-binding 
domain of ER-66 and responding equally to 17- and -estradiol, the molecular similarity 
of these two receptors awaits for the cloning and sequencing of ER-X. 
Additionally, a heterodimeric estrogen-binding protein, referred to as the putative ER 
(pER), was reported to bind to E2 at a sub-nanomolar affinity but was unable to bind 
other estrogens or anti-estrogens. Depending on cell types, pER is expressed on the 
plasma and/or nuclear membranes or in the cytoplasm and nucleus (Rao et al., 1998). 
Since the polyclonal anti-pER antibody failed to react with estrogen receptors and was 
unable to detect pER expression in reproductive organs (Rao et al., 1998), the role of this 
putative estrogen receptor in non-genomic estrogen signaling of breast cancer cells 
remains elusive.  
12. Negative regulation of genomic estrogen signaling by ER-α36 
Comparison of protein structures of ER-66 and ER-36 indicated that ER-36 lacks both 
AF-1 and -2 transcription activation domains but retains the DNA-binding domain and 
dimerization domain. Transient co-transfection assays using a luciferase-expressing reporter 
construct that contains two Estrogen Response Element (ERE) placed upstream of the 
thymidine kinase promoter (2 X ERE-tk-Luc) revealed that ER-36 has no intrinsic 
transcriptional activity in the presence and absence of E2 (Wang et al., 2006). However, ER-
36 strongly inhibited the transactivation activities mediated by the AF-1 and -2 domains of 
both ER-66 and ER- (Wang et al., 2006). These data indicate that ER-36 itself is unable to 
mediate genomic estrogen signaling by regulate target gene expression. However, ER-36 
acts as a naturally occurring dominant-negative regulator of the genomic estrogen signaling 
mediated by the AF1 and AF2 domains of ER-66 and ER-. 
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13. Membrane-association and mitogenic signaling of ER-α36 
The fact that ER-36 posses no intrinsic transcription regulatory activity suggests that ER-
36 may be a membrane-associated estrogen receptor. The sub-cellular fractionation assay 
in ER-36 transfected HEK293 cells revealed that a high percentage of ER-36 (~50%) is 
localized on or near the plasma membrane and a low percentage of it in cytosol (~40%) and 
nucleus (~10%) (Wang et al., 2006). Immuno-fluorescence staining of intact breast cancer 
MCF7 cells and endometrial cancer Hec1A cells using the ER-36 specific antibody 
recognizing the last 20 amino acids that are unique to ER-36 exhibits a membrane 
expression pattern that is co-localized with caviolin-1, a typical cell-surface protein (Lin et 
al., 2010). Immunohistochemistry analysis of specimens from breast cancer patients also 
demonstrated an expression pattern of ER-36 predominantly on the breast cancer cell 
surface (Lee et al., 2008; Vranic et al., 2011). This anti-ER-36 specific antibody also blocked 
ER-36-mediated non-genomic estrogen signaling such as activation of the MAPK/ERK 
signaling in breast cancer cells presumably through steric hindrance of estrogen accesses to 
its binding pocket (Kang et. al., 2010b), indicating that the antibody is accessible to the C-
terminal region of the plasma membrane-associated ER-36 in intact cells. These results thus 
demonstrated that ER-36 is expressed on or near the plasma membrane and suggested that 
ER-36 may be also shuttled to the cell cytoplasm and nucleus depending on cell context 
and extracellular signals.  
Both 17-estradiol (E2) and BSA-conjugated E2 elicit the rapid, membrane-initiated 
estrogen signaling such as activation of the MAPK/ERK signaling pathway and stimulation 
of cell proliferation in ER-36 transfected HEK293 cells, which is not blocked by anti-
estrogens such as tamoxifen, 4-hydroxy-tamoxifen and ICI 182, 780 (Wang et al., 2006). In 
addition, other estrogens including estrone (E1), 17-estradiol (E2), estriol (E3) and estetrol 
(E4) all activate the ERK1/2 phosphorylation at a very similar level (Wang et al., 2006). 
Recently, it was reported that ER-36 even mediated testosterone-stimulated activation of 
the MAPK/ERK and PI3K/Akt signaling pathways in endometrial cancer Hec1A cells (Lin 
et al., 2009). ER-36 also mediates estrogen activation of the PKC/ERK signaling pathway 
(Tong et al., 2010). The finding that the non-genomic estrogen signaling mediated by ER-36 
was insensitive to anti-estrogens suggests that ER-36 may be a receptor involved in the 
anti-estrogen-insensitive estrogen signaling described in different systems before. Taken 
together, ER-36 is a membrane-associated estrogen receptor that mediates rapid and 
mitogenic estrogen signaling. 
14. ER-α36 in anti-estrogen signaling and anti-estrogen resistance 
Since mitogenic estrogen signaling plays a pivotal role in development and maintenance of 
ER-positive breast cancer, treatment with anti-estrogens such as tamoxifen (TAM) has 
become a first-line therapy for advanced ER-positive breast cancer. However, laboratory 
and clinical evidence indicated that TAM and its metabolites such as 4-hydroxytamoxifen 
(4-OHT) have mixed agonist/antagonist or estrogenic/anti-estrogenic actions depending on 
cell and tissue context, and the agonist activity of tamoxifen may contribute to tamoxifen 
resistance observed in almost all patients treated with tamoxifen. As a consequence, a more 
potent and “pure” anti-estrogen, ICI 182, 780 (Fulvestrant, Faslodex) has been developed 
(Reviewed by Howell et al., 2000). 
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TAM and 4-OHT are thought to function as antagonists by competing with E2┚ and other 
estrogens for binding to ERs. Further structural studies revealed that TAM induces an ER-┙ 
conformation that does not recruit coactivators to trans-activate target genes but recruits co-
repressors (Shang et. al., 2000), suggesting that TAM- and 4-OHT-bounded ER-┙66 is unable 
to effectively activate genes involved in cell growth and breast cancer development. On the 
other hand, ICI 182, 780, a ‘pure’ antiestrogen without estrogenic activity, works in a 
different mechanism. ICI 182, 780 binds to ERs, impairs receptor dimerization and inhibits 
nuclear localization of receptor (Fawell, et. al., 1990; Dauvois et. al., 1992). Furthermore, ICI 
182, 780 also accelerates degradation of the ER-┙66 protein without a reduction of ER-┙66 
mRNA (Nicholson et. al., 1995). Thus, ICI 182, 780 binds ER-┙66 and accelerates degradation 
of ER-┙66 protein, resulting in a complete inhibition of estrogen signaling mediated by ER-
┙66. 
Although ICI 182, 780 has been depicted as a non-agonist or ‘full’ or ‘pure’ anti-estrogen, 
different laboratories documented estrogenic agonist activities of ICI 182, 780 in different 
systems. Estrogenic agonist activity of ICI 182, 780 has been found in hippocampal neurons 
and in bone cells where ICI 182, 780 promoted bone growth (Zhao et al., 2006; Sibonga et al., 
1998). Agonist-like activities of ICI 182, 780 have also been reported in tamoxifen-resistant 
KPL-1 breast cancer cells (Kurebayashi et al., 1998) and Yeast (Dudley et al., 2000). Both 
tamoxifen and ICI 182, 780 were also reported to induce phosphorylation of the adhesion 
molecules p130Cas/BCR1, FAK and Src in ER-positive breast cancer MCF7 cells (Cowell et 
al., 2006).  The molecular mechanisms by which ICI 182, 780 acts as an estrogenic agonist 
have never been elucidated. Studies from a number of laboratories suggested that a 
membrane associated estrogen-binding receptor mediates the agonist actions of ICI 182, 780 
in neurons (Reviewed by Brinton 2001; Zhao et al., 2005; McEwen, 2002).  
As described above, ER-36 mediated non-genomic estrogen signaling is insensitive to anti-
estrogens such as TAM and ICI 182, 780 (Wang et al., 2006). ER-36 also mediates agonist 
activities of tamoxifen and ICI 182, 780 such as activation of the MAPK/ERK and the 
PI3K/AKT signaling pathways in breast and endometrial cancer cells (Wang et. al., 2006; Lin 
et. al., 2010). ICI 182, 780 failed to induce degradation of ER-36 (Kang et al., 2010a) 
presumably because ER-┙36 has a truncated ligand-binding domain that lacks the last 4 
helixes (helix 9–12) of ER-┙66 (Wang et al., 2005). The helix-12 domain is critical in protein 
degradation induced by ICI 182, 780 and different positioning of the helix 12 and the F 
domain of ER-66 regulates functional differences between agonists and antagonists 
(Mahfoudi et al., 1995; Pearce et al., 2003). Thus, it is possible that ER-36 is a receptor that 
mediates agonist activities of TAM and ICI 182, 780 recorded in different systems.  
Despite the significant anti-neoplastic activities of anti-estrogens, most breast tumors are 
eventually resistant to anti-estrogen therapy. Essentially, two forms of anti-estrogen 
resistance occur: de novo and acquired resistance (Reviewed by Clarke et. al., 2001 & 2003; 
Ring & Dowestt, 2004). Although absence of ER-66 expression is the most common de novo 
resistance mechanism, about 40-50% ER-positive tumors are already resistant to anti-
estrogens by the time of diagnosis; this de novo resistance mechanism in these ER-positive 
tumors is largely unknown (Reviewed by Clarke et. al., 2001 & 2003; Ring & Dowestt, 2004). 
Furthermore, most initially responsive breast tumors gradually acquire anti-estrogen 
resistance by loss of anti-estrogen responsiveness. The underlying mechanism of breast 
tumors loss their anti-estrogen responsiveness remains unknown. Breast tumors with 
acquired TAM resistance frequently but not always retain levels of ER-66 expression that 
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would still define them as ER-positive tumors (Reviewed by Clarke et. al., 2001 & 2003). 
Therefore, a loss of ER-66 expression is not the major mechanism driving acquired anti-
estrogen resistance. Up-regulation of Erb-B2 (Her2/Neu) and activation of the MAPK 
signaling pathways are usually associated with development of anti-estrogen resistance 
(Reviewed by Clarke et. al., 2001 & 2003; Ring & Dowsett, 2004).  
A recent retrospective study of 896 cases of breast cancer patients revealed that about 40% 
cases of human breast cancer patients were positive for ER-36; about 40% cases ER-positive 
breast cancer co-expressed ER-66 and ER-36 and about 40% cases of ER-negative breast 
cancer that lacked ER-66 expression were positive for ER-36 (Shi et al., 2009). The breast 
cancer patients with tumors expressing high levels of ER-36 were less benefited from 
tamoxifen therapy than those with low levels of ER-36 expression did, and ER-36 
expression is significantly associated with Her2/Neu expression (Shi et. al., 2009). These 
data suggest that high levels of ER-36 expression in breast cancer cells is one of the 
underlying mechanisms of de novo tamoxifen resistance found in ER-positive breast cancer 
patients. 
The aromatase inhibitors (AIs), on the other hand, inhibit the action of the enzyme 
aromatase, which converts testosterone to E2 (estradiol) and androstenedione to E1 
(estrone). The third generation AIs exemplified by anastrazole and letrozole, provides a 
second line therapeutic strategy in advanced ER-positive patients (Reviewed by Santen, 
2003). However, breast cancer cells that express high levels of ER-36 are super sensitive to 
estrogen; activation of the MAPK/ERK in response to an extreme low concentration of 
estrogen, 1 X 10-16 M/L (Zhang et al., 2011). The anastrozole usually suppresses a plasma 
level of E2 to a mean of 2.6 pmol/L and letrozole to a mean of 2.1 pmol/L (Geisler et al., 
2002). These data suggest that breast cancer patients with tumors expressing high levels of 
ER-36 may also be refractory to the third generation of AIs.  
15. ER-α36 in ER-negative breast cancer 
Because of the lack of ER-66 expression, it is prevailingly thought that estrogen signaling is 
not involved in development and progression of ER-negative breast cancer. However, early 
study showed that ovariectomy prevents formation of both ER-positive and –negative breast 
cancers (Nissen-Meyer, 1964). In addition, BRCA1 mutation related tumors, the vast 
majority of which are ER-negative, are also effectively prevented by prophylactic 
ovariectomy (Rebbeck et al., 1999). The increased risk developing breast cancer following 
pregnancy is assumed due to the ability of pregnancy-associated hormones such as estrogen 
to stimulate mammary epithelial cell proliferation. Surprisingly, however, the majority of 
breast cancers that develop following pregnancy are negative for either estrogen and 
progesterone receptors. To explain this contradictory findings, Gupta et al., (2007) proposed 
that estrogen may promote the growth of ER-negative breast cancer via a systemic increase 
in host angiogenesis.  
Rapid activation of the PI3K/Akt pathway in ER-negative breast cancer MDA-MB-231 cells 
that could not be blocked by estrogen antagonists was reported (Tsai et. al., 2001), which was 
explained as estrogen signaling through an ER-independent pathway. Taken together, these 
data suggest that subsets of ER-negative breast cancer cells may retain non-genomic 
estrogen signaling, which may contribute to development and progression of ER-negative 
breast cancers. Several studies demonstrated that ER-36 variant is expressed in established 
www.intechopen.com
 
Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 298 
ER-negative breast cancer cell lines such as MDA-MB-231 and MDA-MB-436 and about 40% 
specimens from ER-negative breast cancer patients (Wang et al., 2006; Lee et al., 2008; Shi et 
al., 2009). Our group recently reported that E2 treatment activated the MAPK/ERK 
signaling pathway, induced expression of growth-promoting genes, c-Myc and cyclin D1, 
stimulated cell proliferation and accelerated tumor growth in vivo in ER-negative breast 
cancer MDA-MB-231 and MDA-MB-436 cells, all of which could be abrogated by knock-
down of ER-36 expression using ER-36 specific shRNA (Zhang et al., 2011). Thus, ER-36-
mediated mitogenic estrogen signaling contributes malignant growth of ER-negative breast 
cancer cells. 
16. Underlying mechanism of mitogenic estrogen signaling mediated by  
ER-α36 
Compelling evidence demonstrated that estrogens up-regulate the expression and function 
of c-Myc and cyclin D1, and activate cyclin E-Cdk2 complexes, all of which are rate limiting 
factors for cell cycle progression from G1 to S phase (Prall et. al., 1998; Altucci et. al., 1996 & 
1997). Based on these findings, it is believed that estrogens directly interact with ERs in ER-
positive human breast cancer cells, where they induce transcriptional activation of 
“immediate early” and cyclin genes and promote cell cycle progression. However, 
membrane-initiated estrogen signaling, including rapid changes of the signal transduction 
cascades, has been proposed to be also essential for the mitogenic action of estrogen 
signaling. Castoria et. al., (1999) reported that NIH3T3 fibroblasts are made equally E2-
responsive in terms of DNA synthesis by transient transfection with either the wild-type or 
the transcriptionally inactive ER-66 mutant. Castoria et. al., (2001) later demonstrated that 
the PI3K/Akt signaling pathway and Src together mediates activation of cyclin D1 promoter 
activity and promotion of the S-phase entry in estrogen–stimulated ER-positive breast 
cancer MCF7 cells. These findings together with other reports (Song et al., 2002; Migliaccio 
et al., 1996; Ahmad et al., 1999; Lobenhofer et al., 2000) highlight the importance of the non-
genomic action of estrogen signaling in estrogen-stimulated cell proliferation and mammary 
tumorigenesis. 
The epidermal growth factor receptor (EGFR) is essential for ductal morphogenesis during 
normal mammary gland development and its overexpression either at the gene or protein 
levels is well documented in human breast cancer (Reviewed by Troyer & Lee, 2001). 
Overexpression of EGFR alone usually does not constitute efficient transformation and 
tumorigenesis in breast cancer models. However, co-expression with the non-receptor 
kinase c-Src dramatically increases tumorigenesis (Maa et al., 1995; Tice et al., 1999; Biscardi 
et al., 1998). Co-expression of EGFR and c-Src in breast cancer cell lines results in their 
association and c-Src-mediated phosphorylation of the EGFR at tyrosine 845 (Tyr845) within 
its catalytic domain, which contributes to enhanced proliferation in vitro and tumor 
formation in vivo (Biscardi et al., 1998; Maa et al., 1995; Tice et al., 1999; Biscardi et al., 2000). 
Accumulating evidence indicated that c-Src is involved in non-genomic estrogen signaling 
by interacting with ER-66 in ER-positive breast cancer cells (Shupnik, 2004). In ER-negative 
breast cancer cells, E2 induced the MAPK/ERK activation through a mechanism that 
involves the interaction between ER-36 and the EGFR/Src/Shc complex (Zhang et al, 
2011). Intriguingly, ER-36 interacts strongly with EGFR in the absence of estrogen and is 
progressively dissociated from EGFR after estrogen treatment (Zhang et al., 2011), which is 
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in contradictory to the finding that estrogen stimulates recruitment of ER-66 to the EGFR 
complex (Reviewed by Levin, 2003). Like ER-66 (Song et al., 2002), interaction between ER-
36 and the Src/Shc was estrogen-dependent (Zhang et al., 2011), which results in Src-Tyr-
416 phosphorylation and phosphorylation of the EGFR-Tyr-845 but not the major auto-
phosphorylation sites of EGFR such as Tyr-992, -1068 and -1073. Tyr-845 in the EGFR is not 
an auto-phosphorylation site and is not required for EGFR kinase activity but is 
phosphorylated by Src (Biscardi et al., 1998).  
Signal transducer and activator of transcription 5b (STAT5b), c-Src and EGFR play 
important roles in estrogen-stimulated proliferation of ER-positive breast cancer cells (Fox et 
al., 2008). Estrogen-induced Src activation and Src-dependent phosphorylation of EGFR-Tyr-
845 recruit STAT5b as a downstream effector of phosphorylated EGFR-Tyr-845 to induce c-
Myc and cyclin D1 expression (Fox et al., 2008). Introduction of a dominant-negative 
STAT5a into ER-positive T47D breast cancer cells inhibits E2-stimulated cell proliferation 
and induces apoptosis (Yamashita et al., 2003). The involvement of STAT5 in ER-36-
mediated estrogen activation of the cyclin D1 promoter activity has been established (Zhang 
et al., unpublished data). Thus, it is possible that ER-36 mediates mitogenic estrogen 
signaling through the EGFR/Src/STAT5 pathway in breast cancer cells. 
17. Transcriptional regulation of ER-α36 
Transcription of ER-36 is initiated from a previously unidentified promoter in the first 
intron of the ER-66 gene (Figure 1). The putative 5’-flanking region of the ER-36 has been 
cloned and sequenced (Zou et al., 2009). Computer analysis revealed a TATA binding 
protein (TBP) recognition sequence upstream of the cDNA start site and several Sp1, NF-B 
and Ap1 binding sites in the 5’-flanking region of ER-36. A perfect half ERE site was 
identified at the promoter region of ER-36 that is involved in suppression of ER-36 
promoter activity by ER-66, indicating that ER-36 expression is subjected to negative 
regulation of ER-66 (Zou et al., 2009). This is consistent with the finding that ER-positive 
breast cancer cells tend to express lower levels of ER-36 compared to ER-negative breast 
cancer cells (Wang et al., 2006; Zou et al., 2009). ER-46 that lacks the AF-1 domain, 
however, had no effect on ER-36 promoter activity while ER-46 released the suppression 
activity of ER-66 when co-expressed with ER-66 (Zou et al., 2009). Thus ER-66 
suppresses the promoter activity of ER-36 presumably through ligand-independent 
activity mediated by its AF1 domain, which can be blocked by ER-46. In addition, co-
expression of ER-36 also released the suppression activity mediated by ER-66 (Zou et al., 
2009), suggesting that ER-36 may be regulated by a positive-feedback mechanism.  
BRCA1 mutations and downregulation are found in familial and sporadic breast cancers and 
BRCA1-related tumors are more likely to be ER-negative than are non-BRCA1 related breast 
cancers. It is still unknown why dysfunctional BRCA1 only predispose to cancers of estrogen 
responsive tissues and why these BRCA1-related breast tumors are often ER-negative. BRCA1 
mediates the ligand-independent transcriptional repression activity of the ER-66 through its 
AF-1 domain (Zheng et. al., 2003). Since ER-66 represses the promoter activity of ER-36 
through its AF-1 domain, it is reasonable to postulate that loss of BRCA1 function either by 
mutations or downregulation may activate ER-36 expression, which then activates ER-36-
mediated mitogenic estrogen signaling that eventually leads to development of breast cancers 
characterized as ER-negative since they lack ER-66 expression. 
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The analysis of ER-36 promoter revealed several important features of transcriptional 
regulation of this potentially important player in estrogen signaling. The finding of several 
NF-B binding sites indicates that ER-36 is subject to regulation by the NF-B signaling 
pathway and by different cytokines that activate the NF-B signaling pathway. The 
existence of Ap-1 binding sites in the ER-36 promoter region raised the possibility that 
growth factor signaling may regulate ER-36 expression, which was confirmed by our 
recent report that EGFR-mediated signaling induces ER-36 expression via one of the Ap-1 
binding sites (Zhang et al., 2011). Thus, further study of the transcription regulation of ER-
36 will provide more information about the mechanisms underlying regulation of ER-36 
mediated non-genomic estrogen signaling in cells and tissues other than mammary gland. 
18. Cross-regulation of ER-α36 and members of the EGFR family 
In ER-positive breast cancer cells, it has been well documented that the cross-
communication between EGFR and ER-66 leads to serine phosphorylation of ER-66 and 
ligand-independent activation of the ER-66-mediated transcription (Kato et al., 1995; 
Bunone et al., 1996). Conversely, EGF signaling is strongly enhanced by the ER-66 in ER-
positive MCF7 cells and anti-estrogen ICI 182, 780 was able to block the EGF signaling 
(Migliaccio et al., 2006). In addition, our group has reported another level of cross-talk 
mechanism by which EGFR and ER-36 positively regulate each other’s expression in triple-
negative breast cancer cells (Zhang et al., 2011); EGFR signaling activates the promoter 
activity of ER-36 and ER-36 stabilizes the steady state levels of EGFR protein. This 
positive feedback loop provides a molecular explanation to the aggressiveness of triple-
negative breast cancer. A similar cross-regulation between Her2/Neu and ER-36 was also 
found (Kang et al., unpublished observations). However, unlike EGFR, ER-36-mediated 
estrogen signaling up-regulates the promoter activity of Her2/Neu gene, suggesting that 
ER-36 positively regulates Her2/Neu expression. This data is consistent with the finding 
that ER-36 expression is significantly correlated with Her-2/Neu expression in specimens 
from breast cancer patients (Shi et al., 2009). Thus, the interplay between growth factor 
receptors and ER-36 may play an important role in development and progression of 
subsets of breast cancer that highly express ER-36.  
19. ER-α36 in osteoporosis 
Non-genomic estrogen signaling plays an important role in bone protection; estrogen is able 
to protect the adult skeleton against bone loss by maintaining a focal balance between bone 
formation and resorption, which mainly results from the opposite effects of osteoblasts 
(OBs) and osteoclasts (OCs). Estrogen has anti-apoptotic effects on OBs and pro-apoptotic 
effects on OCs through an extra-nuclear signaling that leads to activation of the MAPK/ERK 
signaling pathway and kinase-dependent changes in transcription activities (Reviewed by 
Manolagas, 2000; Manolagas et al., 2004). However, the underlying mechanisms of this 
opposite effects of estrogen signaling have not been established. Xie et al., (2011) recently 
reported that the postmenopausal level of E2 induces mitogenic, anti-apoptotic and anti-
osteogenic effects in postmenopausal OBs and pro-apoptotic effects in postmenopausal OCs, 
respectively. ER-36 mediates the effects of post-menopausal-level E2 on proliferation, 
apoptosis, and differentiation of OBs through transient activation of the MAPK/ERK 
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pathway, whereas ER-36 mediates post-menopausal-level E2 induced apoptosis of OCs 
through prolonged or sustained activation of the MAPK/ERK pathway. The levels of ER-
36 expression in bone are positively associated with bone mineral density in post-
menopausal women. Thus, the high levels of ER-36 expression are required for preserving 
bone mass in post-menopausal and menopausal women. 
20. Conclusions 
Most previous studies of estrogen signaling in human breast cancer were focused on the ER-
66, the only known estrogen receptor for many years. The discovery of ER-36 in our 
laboratory, combined with the previous reports of membrane-based ER-46, raised the 
intriguing possibility that ER-36 and ER-46 are also involved in estrogen signaling. Net 
estrogen response in a specific target cell thus depends on absolute and relative levels of the 
regulated expression of full-length and alternatively processed estrogen receptor- 
isoforms.  
It is well established that estrogen stimulates mammary epithelial cell proliferation. 
However, the function of ER-66, ER- and ER-46 in mitogenic estrogen signaling is 
confounding. A plethora of experimental evidence indicates that ER-66, ER-46, and ER- 
negatively regulate mitogenic estrogen signaling in transfected cells, which argue against 
the positive role of these receptors in estrogen-stimulated cell proliferation. Thus far, ER-36 
is the only reported estrogen receptor that mediates mitogenic estrogen signaling and 
stimulates cell proliferation in transfected cells and in ER-negative breast cancer cells that 
lack expression of ER-66, ER-46 and ER- but express high level of endogenous ER-36. 
In addition, the finding that ER-36 functions as a potent dominant-negative regulator of 
the genomic estrogen signaling mediated by ER-66 and ER- implicates that when ER-36 
mediates mitogenic estrogen signalling, it may require the silence of genomic estrogen 
signaling. This again challenges the well-known role of genomic estrogen signaling in 
estrogen-stimulated cell proliferation. 
Accumulating evidence highlights the importance of ER-36-mediated non-genomic 
estrogen signaling in malignant growth of breast cancer and endometrial cancer cells. The 
expression of ER-36 has also been detected in other types of human cancer such as human 
colon cancer and liver cancer (Jiang et al., 2008; Miceli et al., 2011), suggesting that ER-36 
may also involved in initiation and development of human malignancy in non-classical 
estrogen targeting organs. Elucidating the functions of ER-36-mediated non-genomic 
estrogen signaling in different types of human malignancy could provide more informed 
approaches to better understand the underlying mechanisms of mitogenic estrogen 
signaling in mammary carcinogenesis. We hope that further investigation of the function 
and underlying mechanisms of this ER variant in different subtypes of human breast cancer 
and even in the putative breast cancer stem/progenitor cells will lead to development of 
high efficacy, less toxic therapeutic agents for patients affected with mammary 
malignancies. 
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